切换至 "中华医学电子期刊资源库"
高级检索
中华普通外科学文献(电子版)

中华普通外科学文献(电子版) ›› 2023, Vol. 17 ›› Issue (01) : 55 -58. doi: 10.3877/cma.j.issn.1674-0793.2023.01.011

论著

miR-490-3p在胃癌中的表达及其临床价值
陶嵩1, 柳亚魁1, 时依1, 宋国磊1, 王栓虎1,†()   
  1. 1. 233000　蚌埠医学院第一附属医院胃肠外科
  • 收稿日期:2022-10-12 出版日期:2023-02-01
  • 通信作者: 王栓虎
  • 基金资助:
    安徽省高校自然科学研究项目(KJ2020A0584)

Expression of miR-490-3p in gastric cancer and its clinical value

Song Tao1, Yakui Liu1, Yi Shi1, Guolei Song1, Shuanhu Wang1,†()   

  1. 1. Department of Gastrointestinal Surgery, the First Affiliated Hospital of Bengbu Medical College, Bengbu 233000, China
  • Received:2022-10-12 Published:2023-02-01
  • Corresponding author: Shuanhu Wang
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

陶嵩, 柳亚魁, 时依, 宋国磊, 王栓虎. miR-490-3p在胃癌中的表达及其临床价值[J/OL]. 中华普通外科学文献(电子版), 2023, 17(01): 55-58.

Song Tao, Yakui Liu, Yi Shi, Guolei Song, Shuanhu Wang. Expression of miR-490-3p in gastric cancer and its clinical value[J/OL]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(01): 55-58.

目的

探讨miR-490-3p表达水平与胃癌临床病理特征和预后的关系。

方法

通过实时荧光定量PCR（qPCR）方法检测80例胃癌患者的癌组织与癌旁正常组织中miR-490-3p的相对表达量，分析其与临床病理特征的关系，采用Kaplan-Meier曲线、Cox比例风险回归模型进行预后分析。

结果

miR-490-3p在癌组织中的相对表达量为（0.652±0.072），低于癌旁正常组织中的（1.259±0.069），差异有统计学意义（t=40.528，P<0.05）；miR-490-3p表达与浸润深度、淋巴结转移及TMN分期显著相关（P<0.05）；miR-490-3p低表达和高表达患者无进展生存期差异有统计学意义（23个月vs 30个月，χ2=8.583，P=0.03）；miR-490-3p、淋巴结转移及TNM分期是胃癌预后的独立影响因素（HR=2.396、0.472、0.230，均P<0.05）。

结论

miR-490-3p表达降低可促进胃癌的增殖、分化和迁移，可成为胃癌诊断和预后的潜在分子标志物。

关键词: miR-490-3p, 胃肿瘤, 临床病理特征, 预后
Objective

To investigate the relationship between the expression of miR-490-3p clinicopathological features and prognosis of gastric cancer.

Methods

The relative expression of miR-490-3p in cancer tissues and adjacent normal tissues of 80 patients with gastric cancer were detected by quantitative real-time PCR (qPCR), and the relationship between it and clinicalpathological characteristics was analyzed. Kaplan-Meier curve and Cox proportional risk regression model were used for prognostic analysis.

Results

The relative expression of miR-490-3p in cancer tissues was (0.652±0.072), which was lower than (1.259±0.069) of normal adjacent tissues, with a statistically significant difference (t=40.528, P<0.05). The expression of miR-490-3p was significantly correlated with the depth of invasion, lymph node metastasis and TMN staging (P<0.05). There was a significant difference in progression free survival between patients with low expression and high expression (23 months vs 30 months, χ2=8.583, P=0.03). miR-490-3p, lymph node metastasis and TNM stage were independent prognostic factors of gastric cancer (HR=2.396, 0.472, 0.230, all P<0.05).

Conclusion

The down-regulation of miR-490-3p may promote the proliferation, differentiation and migration of gastric cancer, and may become a potential molecular marker for the diagnosis and prognosis of gastric cancer.

Key words: miR-490-3p, Gastric neoplams, Clinicopathological features, Prognosis
表1 引物序列
引物名称 引物序列（5’→3’）
miR-490-3p forward GAAGGGTAGATTTAGGCTGTAT
miR-490-3p reverse CAGTTGAGAAAAAGTTATGCACT
U6 forward CCCTATTTTTGACGCGTTATGTGA
U6 reverse GTGAAAATTACAGGGTCATTTGTG
表2 miR-490-3p表达与胃癌患者临床病理特征的关系(例)
项目 例数 高表达组 低表达组 χ2值 P值
例数 80 32 48    
性别       0.889 0.346
  男 50 22 28    
  女 30 10 20    
年龄(岁)       0.366 0.545
  ≥60 57 24 33    
  <60 23 8 15    
肿瘤直径(cm)       0.076 0.783
  ≥5 44 17 27    
  <5 36 15 21    
分化程度       0.079 0.779
  中、高分化 31 13 18    
  低分化 49 19 30    
肿瘤部位       0.335 0.562
  贲门、胃底 27 12 15    
  胃窦、胃体 53 20 33    
浸润深度       5.275 0.022a
  T1+T2 28 16 12    
  T3+T4 52 16 36    
淋巴结转移       6.601 0.014a
  有 55 17 38    
  无 25 15 10    
TNM分期       6.243 0.012a
  Ⅰ+Ⅱ 31 18 13    
  Ⅲ+Ⅳ 49 14 35    
图1 不同miR-490-3p表达水平的胃癌患者生存曲线
表3 影响胃癌预后的多因素Cox回归分析
因素 β SE Wald P HR 95% CI
上限 下限
miR-490-3p 0.874 0.341 6.561 0.010 2.396 1.228 4.675
浸润深度 -0.430 0.752 0.326 0.568 0.651 0.149 2.842
淋巴结转移 -0.750 0.284 6.979 0.008 0.472 0.271 0.824
TNM分期 -1.471 0.519 8.024 0.005 0.230 0.083 0.635
[1]
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2]
Lazăr DC, Avram MF, Romoșan I, et al. Prognostic significance of tumor immune microenvironment and immunotherapy: novel insights and future perspectives in gastric cancer[J]. World J Gastroenterol, 2018, 24(32): 3583-3616.
[3]
Li Y, Tian D, Chen H, et al. MicroRNA-490-3p and -490-5p in carcinogenesis: separate or the same goal?[J]. Oncol Lett, 2021, 22(3): 678.
[4]
Li J, Mo R, Zheng L. MicroRNA-490-3p inhibits migration and chemoresistance of colorectal cancer cells via targeting TNKS2[J]. World J Surg Oncol, 2021, 19(1): 117.
[5]
Zhang LY, Liu M, Li X, et al. miR-490-3p modulates cell growth and epithelial to mesenchymal transition of hepatocellular carcinoma cells by targeting endoplasmic reticulum-Golgi intermediate compartment protein 3 (ERGIC3)[J]. J Biol Chem, 2013, 288(6): 4035-4047.
[6]
Shen J, Xiao Z, Wu WK, et al. Epigenetic silencing of miR-490-3p reactivates the chromatin remodeler SMARCD1 to promote Helicobacter pylori-induced gastric carcinogenesis[J]. Cancer Res, 2015, 75(4): 754-765.
[7]
Liu B, Li J, Cairns MJ. Identifying miRNAs, targets and functions[J]. Brief Bioinform, 2014,15(1): 1-19.
[8]
Kang NN, Ge SL, Zhang RQ, et al. MiR-490-3p inhibited the proliferation and metastasis of esophageal squamous cell carcinoma by targeting HMGA2[J]. Eur Rev Med Pharmacol Sci, 2018, 22(23): 8298-8305.
[9]
Lu N, Zhang M, Lu L, et al. miRNA-490-3p promotes the metastatic progression of invasive ductal carcinoma[J]. Oncol Rep, 2021, 45(2): 706-716.
[10]
Liu X, He B, Xu T, et al. MiR-490-3p functions as a tumor suppressor by inhibiting oncogene VDAC1 expression in colorectal cancer[J]. J Cancer, 2018, 9(7): 1218-1230.
[11]
张文静, 吴克俭, 谭宁平. 早期胃癌淋巴结转移的危险因素及预后分析[J]. 中国中西医结合消化杂志, 2020, 28(5): 331-337.
[12]
Qin D, Wei R, Zhu S, et al. MiR-490-3p silences CDK1 and inhibits the proliferation of colon cancer through an LLPS-dependent miRISC system[J]. Front Mol Biosci, 2021, 8: 561678.
[1] 李国新, 陈新华. 全腹腔镜下全胃切除术食管空肠吻合的临床研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 1-4.
[2] 陈方鹏, 杨大伟, 金从稳. 腹腔镜近端胃癌切除术联合改良食管胃吻合术重建His角对术后反流性食管炎的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 15-18.
[3] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[4] 李刘庆, 陈小翔, 吕成余. 全腹腔镜与腹腔镜辅助远端胃癌根治术治疗进展期胃癌的近中期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 23-26.
[5] 刘世君, 马杰, 师鲁静. 胃癌完整系膜切除术+标准D2根治术治疗进展期胃癌的近中期随访研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 27-30.
[6] 任佳, 马胜辉, 王馨, 石秀霞, 蔡淑云. 腹腔镜全胃切除、间置空肠代胃术的临床观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 31-34.
[7] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[8] 王露, 周丽君. 全腹腔镜下远端胃大部切除不同吻合方式对胃癌患者胃功能恢复、并发症发生率的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 92-95.
[9] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[10] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[11] 关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[12] 张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[13] 陈晓鹏, 王佳妮, 练庆海, 杨九妹. 肝细胞癌VOPP1表达及其与预后的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 876-882.
[14] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
[15] 郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号